Testing a new psoriasis medicine for children 6 to 17
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new medicine called SHR-1314 for children aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if it safely reduces skin redness, scaling, and thickness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 and 18 years old.
- They must have had plaque psoriasis (red, scaly patches) for at least 6 months.
- The psoriasis must be moderate to severe—covering at least 10% of their body, with thick patches and a score of 3 or more on a doctor's rating scale.
- They cannot have other types of psoriasis, like tiny drops or pus-filled bumps.
- They cannot have had cancer, serious infections (like hepatitis, TB, or HIV), or recent depression or suicidal thoughts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new ointment called RSS0393 in children and teenagers aged 6 to 17 who have plaque psoriasis. The goal is to see if the ointment is safe and how it works in the body. This may offer a new treatment option for those whose psoriasis has not cleared with other treatments.
This study tests a new medicine called IBI112 for teens aged 12–18 with moderate to severe plaque psoriasis. It aims to see if the medicine is safe and can help clear skin better than placebo.
This study tests whether a new ointment called RSS0393 can safely and effectively treat plaque psoriasis (a common skin condition causing red, scaly patches). You would apply it to affected skin areas and be compared to people using a placebo (inactive cream) to see if the treatment works.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study tests an experimental drug, SHR-1139, given as an injection, to see if it can help people with plaque psoriasis who haven't gotten enough relief from other biologic treatments. It aims to improve skin symptoms and quality of life.
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
Hear when a new Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.